课题基金 / 基金详情

Inhibiting Thrombopoietin Receptor (TPO-R) Signaling as a Novel Approach to Target TET2 Mutation-Driven Clonal Hematopoiesis

Inhibiting Thrombopoietin Receptor (TPO-R) Signaling as a Novel Approach to Target TET2 Mutation-Driven Clonal Hematopoiesis
抑制血小板生成素受体 (TPO-R) 信号传导作为靶向 TET2 突变驱动的克隆造血的新方法
批准号:
489650
负责人:
Chan Steven M
金额:
$29.82万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2023
资助国家:
加拿大
项目状态:
未结题
起止时间:
2023-09-01 至 2026-09-01

项目摘要

项目成果

Chan Steven M的其他基金

相似基金

相关文献

中文摘要
翻译
不确定潜能的克隆性造血(CHIP)是指在没有血液疾病证据的个体中存在携带与白血病相关的突变的血细胞。患有CHIP的个体发生疾病的风险明显较高,
英文摘要
Clonal Hematopoiesis of Indeterminate Potential (CHIP) refers to the presence of blood cells carrying mutations associated with leukemia in individuals without evidence of a blood disorder. Individuals with CHIP are at a substantially higher risk of devel
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Inhibiting Thrombopoietin Receptor (TPO-R) Signaling as a Novel Approach to Target TET2 Mutation-Driven Clonal Hematopoiesis
  • 批准号:
    483332
  • 项目类别:
    Operating Grants
  • 资助金额:
    $7.29万
  • 财政年份:
    2023
  • 负责人:
    Chan Steven M
  • 依托单位:
Role of Thrombopoietin Receptor (TPO-R) Signaling in TET2 Mutation-Driven Clonal Hematopoiesis
  • 批准号:
    472513
  • 项目类别:
    Operating Grants
  • 资助金额:
    $7.29万
  • 财政年份:
    2022
  • 负责人:
    Chan Steven M
  • 依托单位:
Repurposing Metformin to Target TET2 Mutation Driven Clonal Hematopoiesis and Malignant Transformation
  • 批准号:
    434508
  • 项目类别:
    Operating Grants
  • 资助金额:
    $41.8万
  • 财政年份:
    2020
  • 负责人:
    Chan Steven M
  • 依托单位:
PINK1 Inhibition as a Novel Therapeutic Strategy to Target Acute Myeloid Leukemia Stem Cells
  • 批准号:
    380799
  • 项目类别:
    Operating Grants
  • 资助金额:
    $25.36万
  • 财政年份:
    2018
  • 负责人:
    Chan Steven M
  • 依托单位:
海外基金